Clinical trial for Liver Transplantation (LT)
Official title Restrictive Fluid Management In Liver Transplantation (REFIL)
ClinicalTrials.gov ID: NCT07695363
What this study is testing
- What it's testing
- The study wants to find out if giving less fluid and using blood‑pressure medicines during liver transplant improves patients' recovery compared to giving more fluid.
- Who it's for
- Adults who are having a liver transplant because of end‑stage liver disease.
- What's involved
- Participants will receive either a restrictive fluid plan (less fluid, blood‑pressure meds, and a small blood draw) or a liberal fluid plan (more fluid) while they are in surgery, and will have follow‑up checks after the operation.
- Time commitment
- The study covers the time of the surgery and the hospital recovery period, with a few follow‑up visits before discharge.
- Time commitment: about 12 months
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adult ≥ 18 years old
- Undergoing liver transplantation (LT)
- End-stage liver disease (ESLD) (with or without hepatocellular carcinoma) as the indication for transplantation.
You likely can't join if
- Undergoing LT for an indication other than ESLD (e.g., acute liver failure, primary liver cancer without ESLD, retransplantation, amyloid neuropathy...
- Undergoing combined solid organ transplantations
- Any of the following conditions:
- severe chronic renal failure (GFR \< 15 ml/minute/1.73 m2 [CKD-EPI equation] or already on renal replacement therapy (RRT))
- severe anemia (hemoglobin level \< 80 g/L)
- hemodynamic instability (norepinephrine equivalent \> 10 ug/min)
See the full eligibility criteria
- Adult ≥ 18 years old
- Undergoing liver transplantation (LT)
- End-stage liver disease (ESLD) (with or without hepatocellular carcinoma) as the indication for transplantation.
- Undergoing LT for an indication other than ESLD (e.g., acute liver failure, primary liver cancer without ESLD, retransplantation, amyloid neuropathy, polycystic liver disease, or any other indication not associated with...
- Undergoing combined solid organ transplantations
- Any of the following conditions:
- severe chronic renal failure (GFR \< 15 ml/minute/1.73 m2 [CKD-EPI equation] or already on renal replacement therapy (RRT))
- severe anemia (hemoglobin level \< 80 g/L)
- hemodynamic instability (norepinephrine equivalent \> 10 ug/min)
- Physician refusal to enroll the patient.
The study team makes the final eligibility decision.
Where it's taking place
- Vancouver, British Columbia, Canada
- London, Ontario, Canada
- Montreal, Quebec, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 12 months per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Vancouver, British Columbia, Canada; London, Ontario, Canada; Montreal, Quebec, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.